[PDF] Top 20 A longitudinal study of abnormalities on MRI and disability from multiple sclerosis

... The study demonstrates that lesion volume on MRI in patients with isolated syndromes and early multiple sclerosis (the first five years of the disease) is of prog- nostic value in assessing ... See full document

... IHW from Bayer Healthcare, Biogen Idec, EMD Serono, Hoffmann La-Roche, Novartis and Teva ...funding from Canadian Institutes of Health Research, Research Manitoba, Multiple Sclerosis Society ... See full document

... Three earlier studies [28-30] have thoroughly investi- gated the lesion contrast of several lesions in each patient. Therefore it might be argued whether selecting only two lesions, though the best distinguishable, in ... See full document

... therapies from baseline to follow-up scans, including 2 subjects who changed to rituximab and 1 subject who switched to alemtuzumab— both monoclonal anti- bodies that impact B-cell ...clusions from 1 or 2 ... See full document

... Neurological disability status was assessed using a neurologist-rated Expanded Disability Status Scale (EDSS) including eight Functional Systems scores (FS) [15]: pyramidal, cerebellar, brainstem, sensory, ... See full document

... each study, we segmented 5 representative axial sections of the brain: sections 50 (through the inferior tem- poral lobes, pons, and cerebellum), 70 (including the midbrain and occipital lobes), 90 (through the ... See full document

... this study had several limitations. First, this was a cross-sectional study where subjects were assessed at one point in time, thus, the results do not show any cause and effect ...MS-related ... See full document

... are from a previous randomized controlled trial with 49 ...Expanded Disability Status Scale (EDSS) [22] score equal or higher than 3 and lower or equal than ...present study was that patients should ... See full document

... The primary limitations of our study stem from its ret- rospective study design. Another caveat is the inclusion of statin-treated patients (22.2% of sample). Because hypercholesterolemia occurs with ... See full document

... to study the effect of natalizumab on GM at- rophy avoiding the marked pseudo-atrophy effect of the drug on brain parenchymal volume, we analysed the cor- tical thickness of RRMS patients treated with natalizu- ... See full document

... pathologic abnormalities elsewhere in the neuraxis—most prominently, the spinal ...stepwise multiple linear regression modeling using only MR imaging variables and an inclusion criterion of P ⬍ ...rived ... See full document

... of multiple sclerosis is its unequal distribution across the ...of multiple sclerosis have been found in Finland, as ...of multiple sclerosis reported anywhere in the world ... See full document

... and disability could lead to a better un- derstanding of the disease pathogenesis and potentially to novel treatment options for ...resulting from mitochondrial and as- trocytic dysfunction as well as ... See full document

... later study (lo n a s e s c u , M o n a c o , S a n dr a, l o n a s e s c u , B u r m e i s t e r , D e p r o s s e and Stern, 1981) s h o we d a s i g n i f i c a n t i n c r e a s e of g l y c e r o l i n c o r ... See full document

... this study aimed to build up and evaluate a model combining neurophysiologic and clinical evaluations to obtain a reliable prediction of the progression of disability in MS patients with particular ... See full document

... this study, the presence, prevalence, and location of phase WM-SAs were investigated in a sample of patients with CIS and ...observations from our find- ings: 1) phase WM-SAs were more prevalent among ... See full document

... This evening discussion was opened by Claire Bom- bardier (Toronto, Canada), who stressed the need to learn more about relations between radiographic signs and functional outcome and impairment of quality of life. Ted ... See full document

... values from 0–8) and the MSWS-12 tertiles (with scores of 0 – 33 representing mild walking im- pairment; 34 – 67 as moderate walking impairment; and 68 – 100 representing severe walking impairment) to ... See full document

... dosage of 44 µg administered by SC injections TIW (TIW) with a dosage of 30 µg administered by IM injections QW over 1 year (Table 2). The primary outcome was the proportion of patients remaining relapse free, which ... See full document

... MS disability; it also included health-related functional impact ...on Multiple Sclerosis (NARCOMS) patient registry has developed validated performance scales (PS) [12,13] in areas including walk- ... See full document